Direct Spinal Therapeutics, Inc. is a medical device company developing a Spinal Cord Stimulation (SCS) product-platform to enhance treatment for chronic back pain and other spinal cord injuries. The company’s IP2 technology is based on collaborative research and joint intellectual property developed by George Gillies, Ph.D., UVA research professor of mechanical and biomedical engineering and Chairman of the University of Iowa’s Department of Neurosurgery Dr. Matthew Howard III.

The LVG Seed Fund invested in DSTI before the close of the 2019 fiscal year to advance the company’s IP2 product development and support regulatory and intellectual property work in advance of a pre-submission meeting with the FDA.